VivoSim Amends Armistice Warrants Alongside $4M Placement
VIVS is trading near its 52-week low of $0.585 (7.7% below the low) on elevated volume (5.5× avg).
Summary
VivoSim Labs priced a $4.0 million private placement of pre-funded and common warrants at $0.85 per share, a premium to the current $0.54 price, signaling demand despite the company's distressed financial position. The deal follows the 10-K going concern warning and a recent $5M milestone payment from Eli Lilly. Separately, the company amended legacy Armistice Capital warrants, resetting the exercise price to $0.85 with a five-year term after stockholder approval, aligning them with the new financing. The placement agent fee is 6.5% of gross proceeds. Proceeds are for working capital, buying time as the company burns cash with minimal revenue.
At the time of this announcement, VIVS was trading at $0.54 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.1M. The 52-week trading range was $0.59 to $5.30. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Wiseek News.